Concepedia

Publication | Open Access

A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection

DOIFull Paper Access

116

Citations

33

References

2024

Year

Katharina A Mayer, Eva Schrezenmeier, Matthias Diebold, Philip F Halloran, Martina Schatzl, Sabine Schranz, Susanne Haindl, Silke Kasbohm, Alexander Kainz, Farsad Eskandary,
New England Journal of Medicine

Abstract

Felzartamab had acceptable safety and side-effect profiles in patients with antibody-mediated rejection. (Funded by MorphoSys and Human Immunology Biosciences; ClinicalTrials.gov number, NCT05021484; and EUDRACT number, 2021-000545-40.).

References

YearCitations

Page 1